Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 5/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16937572 | 0.92 | NR1I2 (0.37) | NR1I2TSHRALDH1A1HPGDALOX15 | |
| SCHEMBL27097163 | 0.82 | CYP1A2 (0.52) | TSHRALDH1A1HPGDHSD17B10TDP1 | |
| SCHEMBL21920584 | 0.81 | CYP1A2 (0.53) | NR1I2TSHRALDH1A1HPGDALOX15 | |
| SCHEMBL19089948 | 0.80 | — | — | |
| SCHEMBL10220699 | 0.79 | CYP2A6 (0.42) | ALDH1A1RAB9AMEN1MAPTKMT2A | |
| SCHEMBL10220838 | 0.79 | CYP2A6 (0.42) | ALDH1A1HPGDTDP1RAB9AKDM4E | |
| SCHEMBL25449345 | 0.79 | PDPK1 (0.52) | ALDH1A1HPGDALOX15HSD17B10TDP1 | |
| SCHEMBL21451242 | 0.79 | CCR9 (0.43) | NR1I2TSHRALDH1A1HPGDALOX15 | |
| SCHEMBL348347 | 0.78 | ALDH1A1 (0.52) | NR1I2TSHRALDH1A1HPGDALOX15 | |
| SCHEMBL30010382 | 0.78 | ALDH1A1 (0.52) | NR1I2TSHRALDH1A1HPGDALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746093-B2 | Nitrogen-containing compound, electronic element, and electronic device | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-09-05 | — | — | US | disclosed |
| US-20230192627-A1 | NITROGEN-CONTAINING COMPOUND, ELECTRONIC ELEMENT, AND ELECTRONIC DEVICE | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-11446389-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | REGENERON PHARMACEUTICALS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20210393623-A1 | Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2021-12-23 | — | — | US | disclosed |
| US-11034684-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10689391-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20200121806-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | REGENERON PHARMACEUTICALS, INC. | 2020-04-23 | — | — | US | disclosed |
| US-10450306-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20190194216-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-9950076-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | REGENERON PHARMACEUTICALS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20170209591-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | REGENERON PHARMACEUTICALS, INC. | 2017-07-27 | — | — | US | disclosed |
| US-20170209591-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | REGENERON PHARMACEUTICALS, INC. | 2017-07-27 | — | — | US | disclosed |
| US-20160375147-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | REGENERON PHARMACEUTICALS, INC. | 2016-12-29 | — | — | US | disclosed |
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450306-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | GPBAR1, SLC10A1, NR1H4 | NR1I2 18/4885TSHR 408/4885ALDH1A1 1577/4885 |
| US-20160375147-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | SLC10A1, HNMT, OGFR | NR1I2 1676/4885TSHR 1150/4885ALDH1A1 317/4885 |
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | GPBAR1, SLC10A1, NR1H4 | NR1I2 18/4885TSHR 408/4885ALDH1A1 1577/4885 |
| US-11746093-B2 | Nitrogen-containing compound, electronic element, and electronic device | SLC43A1, SLC7A5, L1CAM | NR1I2 3131/4885TSHR 4832/4885ALDH1A1 3782/4885 |
| US-20190194216-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | SLC10A1, NR1H4, GPBAR1 | NR1I2 22/4885TSHR 326/4885ALDH1A1 1706/4885 |
| US-20170209591-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | HNMT, SLC10A1, SLC10A2 | NR1I2 1634/4885TSHR 1129/4885ALDH1A1 331/4885 |
| US-20090176774-A1 | Compounds and methods of use | HGF, HGFAC, MET | NR1I2 1741/4885TSHR 3003/4885ALDH1A1 81/4885 |
| US-20210393623-A1 | Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors | PTPN1, PTPN5, PTPN2 | NR1I2 1252/4885TSHR 2764/4885ALDH1A1 2966/4885 |
| US-11034684-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | GPBAR1, SLC10A1, NR1H4 | NR1I2 18/4885TSHR 408/4885ALDH1A1 1577/4885 |
| US-10689391-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | SLC10A1, NR1H4, GPBAR1 | NR1I2 22/4885TSHR 326/4885ALDH1A1 1706/4885 |
| US-20200121806-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | HNMT, SLC10A1, SLC10A2 | NR1I2 1634/4885TSHR 1129/4885ALDH1A1 331/4885 |
| US-11446389-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | HNMT, SLC10A1, SLC10A2 | NR1I2 1634/4885TSHR 1129/4885ALDH1A1 331/4885 |
| US-20230192627-A1 | NITROGEN-CONTAINING COMPOUND, ELECTRONIC ELEMENT, AND ELECTRONIC DEVICE | SLC43A1, SLC7A5, L1CAM | NR1I2 3131/4885TSHR 4832/4885ALDH1A1 3782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.